BioSpace News Archive

Direct participation is accelerating discoveries about the causes of autism and the development of targeted treatments and supports

Ultivue announces the addition of Richard C. Malabre, CPA in the role of Chief Financial Officer, as the company adds to its growing executive team.

PerkinElmer, Inc ., a global leader committed to innovating for a healthier world, today announced that it is serving as a provider and co-developer of assays, instrument solutions and expertise for the PROXIDRUGS Consortium which is zeroing in on research for proximity drugs or PROTACs

Asana BioSciences, a clinical stage biopharmaceutical company, announced that it will present additional positive results from a Phase 2b study evaluating the efficacy and safety of its investigational oral Janus kinase family (JAK) and spleen tyrosine kinase (SYK) inhibitor gusacitinib (ASN002) in adult patients with moderate-to-severe chronic hand eczema (CHE) in a late-breaking research program

- RESOLVE is a non-profit action-based, infertility and family building organization who want to see increased access to all family building options - It’s estimated that nearly 90% of couples in need of infertility treatment go without care

Todos plans to commercialize Videssa in late 2021 to reduce unnecessary biopsies in the $7.19 billion mammogram naïve market and integrate it into its TBIA Platform Provista Diagnostics’ testing lab in the Atlanta, Georgia area is currently performing COVID-19 testing, that will be automated to significantly increase processing capacity Todos expects to employ testing methodologies to expand Provista’s capabilities regarding COVID variant identification

Walgreens Boots Alliance, Inc. announced that its board of directors has declared a quarterly dividend of 46.75 cents per share, unchanged from the previous quarter and an increase of 2.2 percent from the year-ago quarter.

Research finds people with lower income more likely to experience healthcare provider bias, stigma related to chronic pain management

Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, and Samil Pharmaceutical Co. Ltd. (“Samil”), a pharmaceutical company based in the Republic of Korea, announced the execution of a licensing agreement which grants Samil the right to develop and exclusively commercialize lorecivivint (SM04690) for the treatment of knee osteoarthritis

Indivior PLC (LON: INDV) today announced findings from a qualitative study examining the impact of COVID-19 on opioid use disorder (OUD) management and medication for opioid use disorder (MOUD) access in the U.S. which found that 85% of participants agreed that patients with OUD experienced more barriers to care during the COVID-19 pandemic.